BioGend Therapeutics Co., Ltd. (TPEX:6733)

BioGend Therapeutics Revenue

BioGend Therapeutics had revenue of 54.95M TWD in the quarter ending March 31, 2026, with 15.74% growth. This brings the company's revenue in the last twelve months to 229.81M, up 27.98% year-over-year. In the year 2025, BioGend Therapeutics had annual revenue of 222.34M with 32.62% growth.

• Revenue (ttm): 229.81M
• Revenue Growth: +27.98%
• P/S Ratio: 15.31
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 3.52B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	222.34M	54.69M	32.62%
Dec 31, 2024	167.65M	57.74M	52.53%
Dec 31, 2023	109.91M	78.46M	249.51%
Dec 31, 2022	31.45M	22.18M	239.26%
Dec 31, 2021	9.27M	7.88M	565.40%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 9, 2026

Data Sources Report a data error